Overview

Effect of Anti-IgE in Non-Allergic Asthma

Status:
Terminated

Trial end date:
2009-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out if omalizumab is effective in treating non-allergic asthma. The US Food and Drug Administration has approved the use of omalizumab to treat moderate to severe allergic asthma.

Phase:

Phase 2

Details

Lead Sponsor:

Johns Hopkins University

Collaborator:

Genentech, Inc.

Treatments:

Omalizumab